HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.

MLA

Lin, Xiaoyu, et al. “HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.” Molecular Cancer Therapeutics, vol. 16, no. 2, Feb. 2017, pp. 388–96. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-16-0475.

APA

Lin, X., Huang, X., Uziel, T., Hessler, P., Albert, D. H., Roberts-Rapp, L. A., McDaniel, K. F., Kati, W. M., & Shen, Y. (2017). HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues. Molecular Cancer Therapeutics, 16(2), 388–396. https://doi.org/10.1158/1535-7163.MCT-16-0475

Chicago

Lin, Xiaoyu, Xiaoli Huang, Tamar Uziel, Paul Hessler, Daniel H Albert, Lisa A Roberts-Rapp, Keith F McDaniel, Warren M Kati, and Yu Shen. 2017. “HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.” Molecular Cancer Therapeutics 16 (2): 388–96. doi:10.1158/1535-7163.MCT-16-0475.